QA/QC Interview Questions for Pharma Professionals

In short: This guide groups common pharmaceutical Quality Assurance (QA) and Quality Control (QC) interview prompts by topic. Use the cited guidance and the applicable approved specification or procedure to explain your reasoning. Product-specific limits, instrument settings and site procedures do not have one universal answer.

How to answer a technical question

State the applicable market, guideline, pharmacopoeia or approved procedure; explain the scientific or quality rationale; then describe what evidence and records support the conclusion. If a question asks for a number, first identify the product, dosage form, method, equipment and current edition that control that number. Saying what information is needed is more reliable than guessing.

QA systems and GMP

Deviations, changes, OOS results and CAPA

Deviation or change control? Explain the distinction between documenting an unplanned departure from an approved instruction and assessing a proposed planned change before implementation. Use the definitions and workflow in the applicable quality system. Under US CGMP, written production and process-control procedures must be followed, and departures must be recorded and justified (21 CFR §211.100(b)). EU GMP Annex 15 (2015), §§11.1–11.7, describes documented, risk-assessed change control.
How should an out-of-specification (OOS) result be handled? Describe a timely, documented investigation under the approved procedure. In the United States, 21 CFR §211.192 requires investigation of unexplained discrepancies and failures to meet specifications, with the investigation extended to other potentially associated batches when appropriate. Explain how laboratory and manufacturing evidence is assessed; do not describe repeated testing until a passing result appears.
What is CAPA? Explain how corrective action addresses an identified cause and preventive action reduces the chance of recurrence. A good answer links the investigation, action, owner, evidence of completion and effectiveness review under the applicable quality system.
How do mix-up and cross-contamination differ? Define the specific risks in the example given, then describe the controls and investigation route required by the approved site procedures. GMP, GDP and GLP refer to distinct quality frameworks; name the relevant framework instead of treating the acronyms as interchangeable.

Records and retention

When asked about documentation, describe complete, attributable and reviewable records under the applicable procedure. For batch records, EU GMP Part I Chapter 4 §4.11 requires retention for at least one year after the batch expiry date or five years after QP certification, whichever is longer. US batch records must be retained under 21 CFR §211.180(a) for at least one year after the batch expiry date; the regulation provides a separate rule for OTC batches without an expiry date. Longer local-law or marketing-authorisation periods still apply.

Process and cleaning validation

What are validation, a validation protocol and a validation master plan? Explain the documented evidence that a process or method is fit for its intended use, and how plans define scope, responsibilities, tests, acceptance criteria and reporting. Use the terminology in the applicable quality system.
How would you explain process validation and its sampling plan? FDA’s Process Validation: General Principles and Practices (2011, Revision 1) treats validation as lifecycle work and expects the protocol to define sampling and testing with a rationale that supports sufficient statistical confidence. If asked why a “3X” plan is used, explain its documented statistical or risk basis for that process; the number alone is not a general substitute for justification.
How are cleaning limits, maximum allowable carryover (MACO), no-observed-effect level (NOEL), detergent residue and swab recovery addressed? Explain that a limit must be justified for the products, equipment, analytical method and intended use. EU GMP Annex 15 (2015), §§10.5–10.6, requires cleaning limits to be based on a toxicological evaluation; §§10.11–10.13 address sampling, acceptance criteria and demonstrated recovery for the sampling method and material. The interview answer should explain the approved calculation and evidence rather than quote a stand-alone number.
What is the difference between loss on drying (LOD) and water content? Describe the measurement each method is designed to provide, and refer to the approved method. LOD may capture more than water depending on method conditions; do not assume the two results are interchangeable.

Cleaning limits in more detail. For the EU, the health-based exposure limit (HBEL, expressed as a permitted daily exposure, PDE) is derived under the EMA guideline Setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012, first published 24 November 2014) and its Questions and Answers (EMA/CHMP/CVMP/SWP/246844/2018). The Q&A states that HBELs should be established for all medicinal products and that the underlying data should be reassessed periodically. A MACO or residue limit is then calculated from the HBEL, batch sizes, shared equipment surface area and the sampling and analytical method. The EMA texts do not give one universal number for detergent residue or minimum swab recovery. State these as example in-house criteria that the approved protocol must justify: the detergent residue limit (for example, based on the detergent’s own toxicology or a visibly clean plus analytical limit) and the minimum acceptable swab recovery, which the method validation must demonstrate (Annex 15 §§10.11-10.13).

Stability studies

What do stability zones and conditions mean? Adopted ICH Q1A(R2) (2003) gives stability-data recommendations for its scope, including storage conditions and study duration. The product protocol and applicable market requirements determine which conditions, batches, tests, time points and evaluation apply. Do not quote a condition without identifying the product and market.
What happens after a significant change during a stability study? Describe evaluation against the approved protocol and specification, investigation of the result, assessment of impact and documented follow-up. The response depends on the result, product and regulatory commitment.
What are bracketing and matrixing? Explain that these are reduced-design approaches with defined conditions and assumptions, not permission to omit data arbitrarily. ICH Q1D (2002) describes their design and application; the protocol should justify the selected design.
What is photostability testing? Refer to the applicable study protocol and ICH Q1B (1996), which describes photostability testing for new drug substances and products.
What is mean kinetic temperature (MKT), and which parameters are monitored? Explain the concept only in the context of the applicable procedure and data set; it should not be presented as a replacement for the approved storage condition.

See also bracketing and matrixing designs for stability study.

Stability conditions. ICH Q1A(R2) (2003), general case: long-term testing at 25 °C ± 2 °C / 60% RH ± 5% RH or 30 °C ± 2 °C / 65% RH ± 5% RH (minimum 12 months of data at submission), intermediate testing at 30 °C ± 2 °C / 65% RH ± 5% RH (6 months, only needed when 25 °C / 60% RH is the long-term condition), and accelerated testing at 40 °C ± 2 °C / 75% RH ± 5% RH (6 months). The applicant chooses between the two long-term conditions. Q1A(R2) is framed around the ICH regions; for other climatic zones, such as hot and humid markets, check the applicable WHO stability guidance and national requirements. A significant change at accelerated conditions includes, for example, a 5% change in assay from the initial value or failure to meet the acceptance criteria for appearance, physical attributes or functionality tests; where it occurs, Q1A(R2) calls for additional testing at the intermediate condition to be evaluated against the significant-change criteria. The wider response (investigation, shelf-life impact, regulatory commitment) follows the approved protocol.

Mean kinetic temperature. Q1A(R2) does not define MKT. It is a calculated single temperature that expresses the cumulative thermal effect of storage excursions; use the definition in the current pharmacopoeial general chapter or the approved procedure, and treat it as an excursion-assessment aid, not a substitute for the labelled storage condition.

Analytical methods and laboratory instruments

How do method validation, method verification and method transfer differ? Explain the purpose of each in relation to the intended use, compendial status, receiving laboratory and approved procedure. ICH Q2(R2) (2023) addresses validation of analytical procedures; ICH Q14 (2023) covers analytical-procedure development and lifecycle considerations. Use the approved protocol to identify which characteristics and acceptance criteria apply.
How are known and unknown impurity limits set? Start with the applicable approved specification, pharmacopoeial requirements and regulatory filing. ICH Q6A (1999) provides guidance on specifications for new drug substances and products; do not invent an impurity threshold without the substance, route, maximum daily dose and applicable requirements.
How are HPLC or GC, a column, relative response factor (RRF), capacity factor, end-capping, placebo and reference standards handled? Explain the method’s purpose and the relevant sample chemistry, then refer to the validated procedure and current standard or certificate. There is no single column, RRF, standard-potency or storage answer that fits every method.
How would you distinguish calibration, qualification and validation? Explain what is being shown for the instrument, equipment or process and point to its approved protocol and records. Do not treat calibration alone as proof that a method or process is validated.
What does HPLC calibration or dissolution-apparatus performance verification involve? Identify the instrument, configuration, applicable current procedure and acceptance criteria. Avoid giving a universal lamp wavelength, calibration sequence or tablet unless the question names the relevant instrument and compendial method.
How are Karl Fischer standardisation, volumetric-solution validity, LOD/LOQ, toluene in UV checks, sonication and homogenisation explained? Tie the answer to the method principle, reagent or equipment and its approved procedure. For a numerical limit or reagent choice, identify the method and current source first.

Dosage-form and product questions

Common prompts include tablet or capsule disintegration; friability; dissolution sampling, apparatus and Q+5; content uniformity; dry-syrup LOD; compression-room temperature and humidity; and excipients or process controls for sterile dry-powder products. Discuss the test’s purpose, the approved monograph or product specification, and the method’s acceptance criteria. Whether a test applies, and its limit, can depend on dosage form, product, market and current compendial edition. A comparative question such as whether a paddle or basket gives greater release cannot be answered without the product and method conditions.

Compendial tests. The acceptance criteria for friability, disintegration, dissolution (including the staged Q and Q+5% acceptance approach), content uniformity and capsule tests are set by the current general chapters of the pharmacopoeia named in the product specification (for example USP, Ph. Eur. or IP) and by the product monograph or approved specification. The official chapter text is the only source for the exact limits, so in an interview name the chapter, state that the monograph controls, and say you would check the current edition; do not recite limits from memory. Any figure that comes only from a company SOP, such as an in-house sampling frequency or tablet count for apparatus checks, should be called an example in-house criterion (not a pharmacopoeial requirement).

For sterile products, discuss the approved product-specific process, facility controls and validation evidence. Do not turn an interview prompt into a generic sterilisation recipe. Likewise, dry-syrup moisture limits, compression-room conditions, sterile-product excipients, pooling decisions, swab sample hold time and any sampling frequency must come from the applicable approved method or process protocol.

These values are not set by a general regulation; they come from the product’s approved specification, the process validation or development report and the approved protocol. Dry-syrup LOD is an in-house or monograph specification for that product. Compression-room temperature and humidity are limits set from product sensitivity and the site’s environmental-control specification, and are therefore example in-house criteria. Whether dissolution samples are pooled, how long a swab sample may be held, and how often sampling occurs must be justified by the method validation (for example, a sample hold-time study) and stated in the approved protocol.

For instruments, calibration details (polarimeter and melting-point reference standards, lamp and wavelength checks, UV checks, Karl Fischer titrant standardisation, and dissolution apparatus performance verification) come from the equipment SOP, the manufacturer’s manual and the current compendial chapter for that technique. Any frequency, tolerance or reference material that the pharmacopoeia does not state is an example in-house criterion (not a pharmacopoeial requirement) and must be justified in the SOP.

Frequently asked questions

Should I memorise numerical limits for an interview?

Memorise the source and reasoning relevant to your role, but check any number against the current approved specification, method, market and instrument. Explain what information is missing when a question is underspecified.

Is a “3X” sampling plan required for every process-validation study?

Do not present it as a universal requirement. Explain how the protocol’s sampling plan is justified for the process and how the results provide adequate evidence, consistent with FDA’s 2011 process-validation guidance.

Can one stability condition or cleaning limit be used for every product?

No single value should be assumed across products and markets. Use the applicable stability protocol or toxicologically justified cleaning-validation approach and explain its basis.

What should I say if I do not know an exact limit?

Identify the governing source and the product or method details needed, then explain how you would confirm and document the answer rather than guessing.

References

European Medicines Agency, Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities, EMA/CHMP/CVMP/SWP/169430/2012 (first published 24 November 2014): EMA; Questions and Answers, EMA/CHMP/CVMP/SWP/246844/2018: EMA Q&A.
US Food and Drug Administration, Process Validation: General Principles and Practices, Guidance for Industry, Revision 1, January 2011. Official guidance.
US Electronic Code of Federal Regulations, 21 CFR §§211.100(b), 211.180(a) and 211.192, current through 14 October 2026. Part 211.
European Commission, EudraLex Volume 4, Part I, Chapter 4, Documentation, January 2011, §4.11. Official EudraLex index.
European Commission, EudraLex Volume 4, Annex 15, Qualification and Validation, operational 1 October 2015, §§10.5–10.13 and 11.1–11.7. Official Annex 15.
International Council for Harmonisation (ICH), Q1B, Photostability Testing of New Drug Substances and Products, Step 4, 6 November 1996. Official guideline.
ICH, Q1D, Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products, Step 4, 7 February 2002. Official guideline.
ICH, Q2(R2), Validation of Analytical Procedures, final version, 1 November 2023. Official guideline.
ICH, Q6A, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Step 4, 6 October 1999. Official guideline.
ICH, Q14, Analytical Procedure Development, final version, 1 November 2023. Official guideline.
ICH, Q1A(R2), Stability Testing of New Drug Substances and Products, Step 4, 6 February 2003. Official guideline.